Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar ...

【财华社讯】兆科眼科-B(06622.HK)公布，TAB014(公司核心候选药物之一)用于治疗湿性(新生血管)老年黄斑部病变(“wAMD”)第III期临床试验的积极顶线结果。该项临床试验成功达到主要终点及关键次要终点。TAB014的第III期临床试验为一项随机、双盲及非劣效性研究，主要目标为评估接受TAB014治疗的对象群组对比接受Lucentis®治疗的对象群组于第52周的最佳矫正视力(BCVA ...

Next year, President-elect Donald Trump's administration will begin implementing its agenda. The new administration's priorities and positions on certain benefits-related issues are expected to ...

Just 20 years ago, if a person developed wet AMD, vision loss was imminent. But in 2004, a groundbreaking new treatment called anti-VEGF—including drugs such as Lucentis, Eylea, and Avastin—became ...

Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent ...

This week, the Federal Trade Commission (FTC) issued its long-awaited Final Rule on Unfair or Deceptive Fees. When the FTC released the proposed rule over a year ago, the rule covered any business ...

Melgen stood accused of routinely administering unnecessary, invasive treatments and profiteering off the macular-degeneration drug Lucentis. He was also charged with running millions of dollars' ...